Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310085 | 0.87 | CHRNA7 (0.56) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5306566 | 0.86 | SMN1; SMN2 (0.62) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL14664078 | 0.85 | ALDH1A1 (0.53) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL14828729 | 0.85 | CHRNA7 (0.51) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL15347856 | 0.83 | CHRNA7 (0.55) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL13753541 | 0.82 | NPSR1 (0.61) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5311981 | 0.81 | CHRNA7 (0.50) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5311984 | 0.81 | SPHK1 (0.52) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL10272555 | 0.78 | NPSR1 (0.67) | CHRNA7ALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL29106503 | 0.77 | L3MBTL1 (0.52) | ALDH1A1SMN1; SMN2LMNAMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | CHRNA7 4832/4885ALDH1A1 3778/4885SMN1; SMN2 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.